Overview
The goal of the study is to look at the relationship between how individuals with Sarcoidosis take the sarcoidosis medicines and how it affects the disease, to evaluate any factors that may make individuals not want to take the medicines, and to develop and refine ways to help support individuals with Sarcoidosis especially when it comes to the medicines. The overall hypothesis is higher medication adherence will be associated with better clinical outcomes in sarcoidosis. The investigators will enroll 150 patients with biopsy proven pulmonary sarcoidosis for at least one year who are on any oral treatment regimen for at least six months into a 12-month longitudinal study.
Eligibility
Inclusion Criteria:
- At least 18 years of age.
- Physician diagnosis of Sarcoidosis.
- Biopsy proven pulmonary involvement of Sarcoidosis.
- On oral Sarcoidosis medications for at least 6 months.
- Permanently reside in Maryland or D.C.
- Fully vaccinated against COVID-19.
Exclusion Criteria:
- Non-english speaking.
- Unable to provide consent.
- Unable to participate in orally administered questionnaires.